Long Term Clinical Outcomes of Treatment of In-Stent Restenosis With Drug Eluting Stents

Abstract

Background: Optimal treatment for instent restenosis (ISR) is an enigma, with drug eluting stents (DES) currently regarded as the treatment of choice. We report the clinical outcome of patients undergoing treatment of ISR with DES over a 5-year period among other treatment modalities. Method: Patients with symptomatic ISR (diameter stenosis of >50%) from January 2003 to January 2008 were analysed for long term clinical outcomes of Readmission MI and Death. Results: 215 ISR lesions were recorded in 207 patients. 199 (92.6%) were baremetal stent (BMS) ISR and 16 (7.4%) wereDES ISR. Themean followupwas 30.6± 17.5months. The ISR lesion classification was Type I in 67%; II in 16%; III in 8% and IV in 9%. Treatment of ISR was DES in 130 (60.5%), BMS in 12 (5.6%), Plain Balloon Angioplasty (POBA) in 27 (12.6%), CABG in 17 (7.9%) and medical in 29 (13.5%) patients. A total of 24 deaths occurred in the g